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Background: The prevalence of methicillin-resistant Staphylococcus aureus (MRSA) respiratory infection in cystic
fibrosis (CF) has increased dramatically over the last decade, and is now affecting approximately 25% of patients.
Epidemiologic evidence suggests that persistent infection with MRSA results in an increased rate of decline in FEV1
and shortened survival. Currently, there are no conclusive studies demonstrating an effective and safe treatment
protocol for persistent MRSA respiratory infection in CF.
Methods/Design: The primary objective of this study is to evaluate the safety and efficacy of a 28-day course
of vancomycin for inhalation in combination with oral antibiotics in eliminating MRSA from the respiratory
tract of individuals with CF and persistent MRSA infection. This is a two-center, randomized, double-blind,
comparator-controlled, parallel-group study with 1:1 assignment to either vancomycin for inhalation (250 mg
twice a day) or taste-matched placebo for 28 days in individuals with cystic fibrosis. In addition, both groups
will receive oral rifampin, a second oral antibiotic – trimethoprim/sulfamethoxazole (TMP/SMX) or doxycycline,
protocol determined – mupirocin intranasal cream, and chlorhexidine body washes. Forty patients with persistent
respiratory tract MRSA infection will be enrolled: 20 will be randomized to vancomycin for inhalation and 20 to a
taste-matched placebo. The primary outcome will be the presence of MRSA in sputum respiratory tract cultures
1 month after the conclusion of treatment. Secondary outcomes include the efficacy of the intervention on: FEV1%
predicted, patient reported outcomes, pulmonary exacerbations, and MRSA colony-forming units found in respiratory
tract sample culture.
Discussion: Results of this study will provide guidance to clinicians regarding the safety and effectiveness of a
targeted eradication strategy for persistent MRSA infection in CF.
Trial registration: This trial is registered at ClinicalTrials.gov (NCT01594827, received 05/07/2012) and is funded by
the Cystic Fibrosis Foundation (Grants: PMEP10K1 and PMEP11K1).
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Cystic fibrosis (CF) is the most common lethal auto-
somal recessive disorder in the Caucasian population
[1]. With improvements in care, the average age of indi-
viduals living with CF continues to increase, with me-
dian predicted survival age now nearing 40 years [2].
One consequence of improving survival is the emer-
gence of pulmonary infections with new and resistant
pathogens. These infections are of importance because
they may lead to respiratory failure, which continues to
be the leading cause of mortality in individuals with CF.
Methicillin-resistant Staphylococcus aureus (MRSA) is a
particularly important emerging pathogen in CF. The
prevalence of infection with MRSA in the CF community
has increased from 4% in 1999 to 26.5% in 2012 [2].
Multiple observational studies utilizing the CF Foun-
dation’s National Patient Registry database have demon-
strated that infection with MRSA is associated with
worse clinical outcomes [3-5]. Dasenbrook et al. demon-
strated that persistent respiratory infection with MRSA
is associated with a more rapid decline in lung function
as measured by forced expiratory volume in one second
(FEV1) percent predicted [3,4]. Sanders et al. suggested
that MRSA is associated with failure to recover baseline
lung function after a pulmonary exacerbation [5]. Finally,
the hazard of death was significantly increased in CF pa-
tients with MRSA compared to CF patients without
MRSA, even after adjustment for severity of illness.
Given the striking increase in both prevalence of
MRSA infection in CF and evidence of a detrimental
effect of MRSA on CF clinical outcomes, there has been
growing interest in treatment protocols designed to treat
and/or eradicate respiratory-tract MRSA in CF.
There have been several clinical studies in CF asses-
sing MRSA treatment regimens and their effectiveness
in eradicating MRSA from the respiratory tract. These
studies have been limited by small study populations,
lack of control groups, single-center retrospective design,
variable follow-up, and failure to distinguish incident vs.
persistent MRSA infection [6-9]. A retrospective review of
37 patients at an adult CF center in Manchester, UK, who
had at least one positive MRSA culture and were treated
with a combination of two oral antibiotics and nebulized
vancomycin (200 mg four times a day for 5 days), re-
ported that 81% of treated patients achieved MRSA
eradication at 6 months [9]. A smaller study of seven adult
CF patients with persistent MRSA found that five patients
were culture-negative after completing a 6 month treat-
ment of oral fusidic acid and rifampin [6]. Two studies that
focused on the treatment of incident MRSA infection in
CF reported eradication rates of 94% in 17 patients, using a
combination of oral and IV antibiotics, and 55% in 15 pa-
tients treated with 5 days of oral and nebulized vanco-
mycin (4 mg/kg/dose) [7,8].There have been numerous reports of the clinical use
of nebulized vancomycin in both CF and non-CF popu-
lations, all of which have demonstrated it to be well-
tolerated and efficacious. The doses reported in those
aged >12 years of age have included 125 mg twice a day,
250 mg four times a day, and 500 mg twice a day [10].
In the largest study to date, 51 non-CF patients received
125 mg of nebulized vancomycin twice a day for an aver-
age of 14.7 days to eradicate respiratory MRSA [11].
Eradication success rate was 84.3%. The authors re-
ported that there were no adverse events associated with
inhalation of vancomycin in the 51 participants. Add-
itionally, a pilot study investigating the safety and toler-
ability of nebulized vancomycin in CF patients utilizing a
single dose of 250 mg for inhalation in 10 patients found
that it was safe and well tolerated [12]. All 10 patients
tolerated the entire test dose without significant side ef-
fects, hypoxia, or evidence of sputum eosinophilia, and
the mean relative change in FEV1 (L) 30 minutes after
administration was −3.7% (range: −9.9% to +13.78%),
demonstrating no significant bronchoconstrictive effect
of vancomycin inhalation. Finally, there is significant
clinical experience with the use of nebulized vancomycin
in CF, as the CF treatment community frequently uses neb-
ulized vancomycin in clinical care. A national compound-
ing pharmacy which supplies nebulized vancomycin for
clinical care to CF healthcare providers, reports treatment
of over 95 CF patients with the dose described in the
protocol without any reported treatment related serious
adverse events [personal communication].
We are conducting a randomized controlled trial to
determine if inhaled vancomycin for 28 days, in combin-
ation with an oral antibiotic regimen, can effectively
eradicate MRSA from the respiratory tract of CF pa-
tients who are known to be persistently infected. We
hypothesize that the use of such a strategy can result in
MRSA clearance from the respiratory tract one month
after completion of the protocol. The goal of this study
is to determine if the 28-day combined inhaled vanco-
mycin and oral antibiotic regimen is an effective and safe
method of clearing persistent MRSA infection in CF.
Methods/Design
This is a two-center, double-blind, comparator-controlled,
randomized, and stratified by center and forced expiratory
volume in one second percentage of predicted (FEV1%)
(FEV1% ≤60% and FEV1% >60%), parallel-group study
with 1:1 assignment to either vancomycin for inhalation
(250 mg twice a day) or taste-matched placebo for 28 days
in individuals with cystic fibrosis and chronic MRSA pul-
monary infection. In addition, both groups will receive oral
rifampin, a second oral antibiotic (TMP-SMX or doxy-
cycline, protocol determined), mupirocin intranasal oint-
ment, and chlorhexidine body washes. Forty patients
Jennings et al. Trials 2014, 15:223 Page 3 of 9
http://www.trialsjournal.com/content/15/1/223with persistent respiratory tract MRSA infection will be
enrolled: 20 will be randomized to vancomycin for inhal-
ation and 20 to a taste-matched placebo.
All subjects will provide informed consent prior to en-
rollment in the study. Each subject will be administered
study medication twice a day for 28 days. Subjects will
be randomly assigned to the treatment or placebo. Eval-
uations will be taken at each of the six study visits. All
subjects who receive at least one dose of study medica-
tion will be considered evaluable for safety and efficacy
analyses. Incidence of adverse events will be monitored
beginning at the time of consent. Efficacy assessments
will be based on change in culture results, lung function,
sputum MRSA density, cystic fibrosis quality of life
questionnaire – revised (CFQ-R) scores, and number of
exacerbations.
Total duration of subject participation will be 146 ±
9 days.
This study has been approved by the Institutional
Review Boards at the Johns Hopkins University School
of Medicine (Reference #: NA_00017536) and Case
Western Reserve University School of Medicine (Reference
#: 026513). Additionally, the U.S. Food and Drug Adminis-
tration has granted an Investigational New Drug permit
(IND # 114966) for sterile vancomycin 250 mg to be
reconstituted in 5 mL sterile water and nebulized after
reviewing this study protocol.
Patient population
Subjects with a diagnosis of CF who meet the inclusion
and exclusion criteria will be eligible for participation in
this study. Inclusion and exclusion criteria are listed in
Table 1. Criteria are designed to assure that only stable
CF patients with persistent respiratory MRSA infection
are studied.
Trial intervention
Study participants will be randomized to receive nebu-
lized vancomycin or taste-matched placebo. Nebu-
lized vancomycin will be administered as 250 mg in
5 cc of sterile water, nebulized twice a day for 28 days.
Placebo will consist of volume-matched (5 cc) and
taste-matched (quinine 0.1 mg/mL) nebulized sterile
water. Patients will use a Pari Sprint nebulizer and Pari
Vios compressor as the delivery system, with a Pari
Expiratory Filter to minimize environmental contam-
ination with nebulized vancomycin. Patients will also
be provided with an albuterol HFA MDI and instructed
to take two puffs at home 5 to 60 minutes prior to study
drug inhalation.
All study participants will receive oral rifampin (>45 kg:
600 mg daily; 35–35 kg: 450 mg daily; 25–34.9 kg: 300 mg
daily), and oral trimethoprim/sulfamethoxazole (>45 kg:
two DS tablets twice a day; 25–45 kg: one DS tablet twicea day). If a study participant is sulfa intolerant or their
MRSA culture is trimethorpim/sulfamethoxazole (TMP/
SMX) resistant, then they will receive oral doxycycline
(>45 kg: 100 mg twice a day; 35–45 kg: 75 mg twice a day;
25–34.9 kg: 50 mg twice a day). Oral antibiotics will be ad-
ministered for 28 days, in conjunction with the nebulized
study drug.
To address potential nasal colonization with MRSA,
study participants will be instructed to use mupirocin
2% intranasal ointment for the first 5 days of the treat-
ment period: half of a single use tube applied into each
nostril, twice a day. To address potential MRSA colo-
nization of the skin, subjects will also be instructed to
use Hibiclens 15 cc liquid skin cleanser packets (4%
chlorhexidine gluconate) once weekly in the shower
for 4 weeks to minimize body colonization. Finally, to
address potential home sources of MRSA, participants
will wipe down all high-touch home surfaces with
Sani-Cloth Alcohol Free Germicidal wipes and wash
bed linen and towels in hot water weekly for the first
three weeks of the study. See Table 2 for a list of study
interventions.
All of the participant’s usual CF medications and treat-
ments are allowed except non-study anti-MRSA antibi-
otics beginning 2 weeks prior to the screening visit and
throughout the study (unless medically indicated). Subjects
should remain on a stable medical regimen throughout the
entire study period, with the exception that patients on
continuous inhaled antibiotics will stop their non-study
drug inhaled antibiotic during the 28 day treatment period.
If subjects are on an alternating 28-day “on”/”off” cycle of
an inhaled antibiotic, study drug dosing will occur during
the “off” cycle. There will be no introduction of other new
chronic therapies during the study period unless medically
required.
Randomization
Up to 40 eligible patients will be enrolled and randomly
assigned to vancomycin for inhalation or placebo treat-
ment in a 1:1 ratio using a SAS-based, computer-
generated randomization scheme. The randomization
will be performed in blocks of random sizes and
stratified by FEV1% and center. The randomization
will also be designed to assure an equal division be-
tween placebo and treatment among the first 16 partic-
ipants in preparation for the first data and safety
monitoring board (DSMB) safety review (after 16 par-
ticipants are enrolled). After the initial DSMB safety re-
view and approval, eligible subjects aged 12–17 years
may be enrolled.
Blinding
The identity of test and control treatments will not be
known to investigators, research staff, or patients. The
Table 1 Study inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
● Male or female ≥12 years of age ● An acute upper or lower respiratory infection, pulmonary exacerbation,
or change in routine therapy (including antibiotics) for pulmonary disease
within 42 days of the Day 1 visit (2 weeks prior to screening visit)
● Confirmed diagnosis of CF based on the following criteria: ● Individuals on continuous inhaled antibiotics without interruption
who are not willing to substitute vancomycin or placebo for their
scheduled inhaled antibiotic during days 0–28 of the study● 1. Positive sweat chloride >60 mEq/L (by pilocarpine iontophoresis)
and/or
● 2. A genotype with two identifiable mutations consistent with CF
or abnormal nasal potential difference, and
● 3. One or more clinical features consistent with the CF phenotype
● Written informed consent (and assent when applicable) obtained from
subject or subject’s legal representative and ability for subject to comply
with the requirements of the study
● Use of oral or inhaled anti-MRSA drugs within two weeks of the
screening visit
● Two positive MRSA respiratory cultures in the last 2 years at least
6 months apart, plus a positive MRSA respiratory culture at the
screening visit and run-in (Day −14) visit
● History of intolerance to inhaled vancomycin or inhaled albuterol
● At least 50% of respiratory cultures from the time of the first MRSA
culture (in the last 2 years) have been positive for MRSA
● History of intolerance to rifampin or both trimethorpim/
sulfamethoxazole (TMP/SMX) and doxycycline
● FEV1 > 30% of predicted normal for age, gender, and height at screening ● Resistance to rifampin or both TMP/SMX and doxycycline at screening
● Females of childbearing potential must agree to practice an acceptable
method of birth control (in the opinion of the investigator), including
abstinencea. Female patients who utilize hormonal contraceptives as a
birth control method must have used the same method for at least
3 months before study dosing
● Resistance to vancomycin at screening
● Abnormal renal function, defined as creatinine clearance <50 mL/min
using the Cockcroft-Gault equation for adults or Schwartz equation in
children, at screening
● Abnormal liver function, defined as ≥3x upper limit of normal, of
serum aspartate transaminase or serum alanine transaminase, or
known cirrhosis at the time of screening
● Serum hematology or chemistry screening results which in the
judgment of the investigator would interfere with completion of
the study
● History of or listed for solid organ or hematological transplantation
● History of sputum culture with non-tuberculous Mycobacteria in
the last 6 months
● History of sputum culture with Burkholderia Cepacia in the last year
● Planned continuous use of soft contact lenses while taking rifampin
and no access to glasses
● Current use of oral corticosteroids in doses exceeding the equivalent
of 10 mg prednisone a day or 20 mg prednisone every other day
● Taking voriconazole and unable to discontinue its use from run-in
visit to Day 29 end-of-treatment visit
● Administration of any investigational drug or device within 28 days
of screening or within 6 half-lives of the investigational drug
(whichever is longer)
● Patients on inhaled antibiotics must have been on the same
regimen for the 4 months prior to screening
● Female patients of childbearing potential who are pregnant or
lactating, or plan on becoming pregnant
● Any serious or active medical or psychiatric illness, which in the
opinion of the investigator, would interfere with patient treatment,
assessment, or adherence to the protocol
a) Full details available in protocol.
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Table 2 Study interventions
Intervention arm (n = 20) Placebo arm (n = 20) All study participants (Intervention + Placebo arms)
● Vancomycin: 250 mg/5 cc sterile water
nebulized two times a day, Days 1–28
● Placebo: quinine 0.5 mg/5 cc sterile water
nebulized two times a day, Days 1–28
● Oral Rifampin: Days 1–28
● 1. >45 kg: 600 mg by mouth daily
● 2. 35–45 kg: 450 mg by mouth daily
● 3. 25–34.9 kg: 300 mg by mouth daily
● Oral TMP/SMXa (DS-160/800):
Days 1–28
OR ● Oral Doxycyclineb:
Days 1–28
● 1. >45 kg: Two DS tabs by
mouth twice a day
● 1. >45 kg: 100 mg by
mouth twice a day
● 2. 25–45 kg: One DS tab by
mouth twice a day
● 1. 35–45 kg: 75 mg by
mouth twice a day
● 2. 35–45 kg: 75 mg by
mouth twice a day
● Mupirocin 2% intranasal ointment: apply to each nasal cavity
twice a day for Days 1–5 of study
● Hibiclens (4% chlorhexidine gluconate) liquid skin cleanser:
use three packets once weekly in the shower, Days 1–28
● Wipe down of high touch household surfaces with Sani-Cloth
Alcohol Free Germicidal wipes: use once a week, Days 1–28
● Wash all linen and towels in hot water: weekly, Days 1–21
aParticipants with MRSA susceptible by MIC testing to TMP/SMX and without history of sulfa allergy will be treated with trimethoprim/sulfamethoxazole.
bParticipants with MRSA resistant by MIC testing to TMP/SMX and without history of doxycycline allergy will be treated with doxycycline.
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double-blind administration of study treatments:
 Access to the randomization code will be strictly
controlled. Access to the randomization code will be
limited to the randomization programmer, manager
of the data management unit as a backup to the
randomization programmer, and the drug packaging
group.
 Packaging and labeling of test and control treatments
will be identical.
 Measured serum and sputum vancomycin levels will
not be available to the investigators until data base
lock.
 The study blind will be broken on completion of the
clinical study and after all adverse events have been
evaluated for relationship to study drug, coded, and
reviewed by the DSMB.
 During the study, the blind may be broken only in
emergencies when knowledge of the patient’s
treatment group is necessary for further patient
management.
Participant follow-up
Study participants will be followed for up to 155 days.
The duration of subject participation will include:
Screening/Run-in: up to 30 days; Treatment: 28 days;
Primary Endpoint: Day 58; Follow-up: 3 months after com-
pletion of 28-day treatment period. See Table 3 for acomplete list of study visits, events, and study procedures
by event.
Outcome measures
The primary outcome of this study is the percentage of
patients MRSA free by induced sputum respiratory tract
culture 1 month (Visit 5, Day 58) after completion of
4-week eradication protocol in intervention arm vs.
control arm.
Secondary efficacy outcomes include: i) percentage
of patients MRSA free at visit 4 (Day 29) and Visit 6
(Day 118); ii) change in FEV1 from baseline (Day 1)
at visit 4 (Day 29), Visit 5 (Day 58) and visit 6 (Day 118);
iii) change in FEV1 from screening (Day −28) at Visit 4
(Day 29), visit 5 (Day 58) and visit 6 (Day 118); iv) time
to first pulmonary exacerbation, measured from Day 1;
v) total number of exacerbations at visit 5 (Day 58) and
visit 6 (Day 118); vi) change in patient reported CFQ-R
(respiratory) from baseline (visit 1) to visit 3 (Day 14),
visit 4 (Day 29), visit 5 (Day 58), and visit 6 (Day 118); 7)
number of patients with newly developed MRSA resistance
to vancomycin, TMP/SMX, doxycycline, and/or rifampin
at any point during follow-up.
Secondary safety outcomes include: i) chemistry panel,
aspartate transaminase, alanine transaminase, alkaline
phosphatase, and complete blood count with differential,
at screening (Day −28), visit 3 (Day 14), visit 4 (Day 29),
and visit 5 (Day 58); ii) incidence of adverse events; iii) con-
tinuous oxygen saturation throughout first nebulized












































X X X X
Abbreviated physical
exam
X X X X X
Height, weight X X X X X X X X X
Vital signs, oximetry (b) X X Xb Xb Xb X X X X
CFQ-R (c) X X X X X X
Administer albuterol (d) X X X X X X X X X
Spirometry (e) X X Xe Xe X X X X X
Sputum induction
procedure (f)
X X X X X X X
Sputum culture and
sensitivity
X X X X X X X
Sputum MRSA colony
forming units (g)
X X X X X Xo
Small colony variants
of MRSA (g)
X X X X X X X
MRSA: comprehensive
genetic strain analysis (g)
X X X X X X X





























Table 3 Schedule of study visits (Continued)
Chemistry/LFTs/
hematology/CRP
X X X X X Xp
Pregnancy test
(Urine or Serum) (l)
Xl Xl Xl
Initiate subject diary X
Subject diary review X X X X X X X Xp
Concomitant medication
review
X X X X X X X X X X X
Adverse experiences
review

















Collect used and unused
study drug and containers
X X Xp
aSpontaneous expectorated sputum collected 5 ± 4 minutes after nebulizing study drug. Gargle with 30 cc of saline for ten seconds x3 prior to collection.
bPeak drawn 60 ± 10 minutes after end of nebulization on day 1; trough drawn with other blood tests prior to nebulization on day 14.
cSerum pregnancy test done at screening, urine at other time points.
dWash with water and one packet of Hibiclens hand cleanser for 2 minutes. Skin reaction will be observed for 15 minutes after washing.
eRandomization will be a non-visit task on Day −4 (±3 days) once culture results from run-in visit confirm presence of MRSA.
fCFU’s will be done if early withdrawal visit occurs between visit 2 and visit 4.
gIf applicable, only if early withdrawal visit occurs between visit 1 and visit 4.
hIf applicable, only if early withdrawal visit occurs before visit 3.
iHistory of previous treatment for MRSA, number of MRSA cultures, and length of MRSA positivity at screening visit.
gContinuous pulse oximetry is performed during nebulization of study drug and for 5 minutes afterward on Days 1, Repeat admin visit and Day 14. Observe for 1 h post-treatment.
kOn days CFQ-R is performed, it is done before any other interventions.
lTwo puffs of Albuterol HFA 10–30 minutes prior to spirometry and 10–60 minutes prior to study drug nebulization on Days 1 and 14.
mSingle spirometry value also obtained immediately after and 15 minutes after study drug nebulization on Day 1 and Repeat Administration Day.
nFollow TDN Sputum Induction protocol 517.01; throat swab if inadequate sputum produced.
oOnly if culture grows MRSA.
pFollow TDN Sputum Processing Protocol 508.01.
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and 15 min (±10 min) after first nebulized vancomycin
dose; v) hand washing with chlorhexidine body wash at
visit 1 (Day 1) to monitor for skin sensitivity.
Additional secondary outcomes include: i) serum vanco-
mycin peak level 60 minutes after completion of first dose
of inhaled vancomycin at visit 1; ii) trough serum
vancomycin level to be drawn prior to nebulization of
vancomycin at visit 3 (Day 14 – 2 weeks into nebulized
vancomycin); iii) sputum vancomycin level at visit 3
(Day 14), 30 minutes after nebulizing vancomycin in pa-
tients; iv) change in minimum inhibitory concentration
(MIC) of vancomycin, rifampin, TMP/SMX, and tetra-
cycline for MRSA. Centers for Disease Control and
Prevention guidelines classify MRSA as vancomycin-
intermediate Staphylococcus aureus if the MIC for
vancomycin is 4–8 μg/mL, and classify MRSA as
vancomycin-resistant Staphylococcus aureus if the vanco-
mycin MIC is ≥16 μg/mL. We will also monitor for those
MIC’s that are initially less than 2 μg/mL and convert to
2 μg/mL; 5) rectal swabs at run-in visit (Day −14), visit 4
(Day 29), and visit 5 (Day 58) to screen for the develop-
ment of vancomycin-resistant enterococcus.
Statistical analysis
The following demographic variables at screening will be
summarized by treatment arm: race, gender, age, height,
and weight. All eligible patients who are randomized
into the study and receive at least one dose of the study
drug (the Safety Population) will be included in the
safety analysis.
Our hypothesis for our primary outcome states that
the treatment arm will result in significantly greater
eradication of persistent MRSA from the respiratory
tract of CF adolescents and adults compared to the pla-
cebo arm on day 58. Our primary analysis will include
comparing the proportion of CF patients in the treat-
ment arm who have a negative MRSA culture at visit 5
to the proportion of patients in the placebo arm who
have a negative MRSA culture at visit 5. Secondary ana-
lyses will include the above comparisons, but at visits 4
and 6. χ2 or Fishers exact test will be used to determine
statistical significance. A secondary analysis will also be
performed comparing proportions of MRSA positive
cultures among the three cultures obtained at visits 3, 4,
and 5 during the study. Generalized estimating equations
(GEE), using a logit link, will be used to model this longi-
tudinal data. The GEE model will be used to test for main
effects of treatment arm, time, and treatment × time
interaction. Furthermore, sensitivity analyses will be per-
formed to evaluate the robustness of the primary out-
come to missing culture data (missing data should be
minimal) using i) imputation with last observation car-
ried forward and multivariate imputation by chainedequations, ii) treating all missing cultures as negative,
and iii) treating all missing cultures as positive. Finally,
the statistical analyses, evaluating both primary and sec-
ondary outcomes, will be adjusted for the presence of
Pseudomonas positive sputum cultures, as well as for the
concurrent use of azithromycin during the course of the
study period.
Our hypothesis for the secondary outcomes states that
the treatment arm will improve clinical measures (lung
function, quality of life, and exacerbations) compared to
placebo. Statistical significance for differences in lung
function (FEV1%) at visit 4 will be assessed between the
two treatments using a 2-sample t-test. We will use lin-
ear mixed models to longitudinally analyze and compare
the change in lung function over 155 days in the two
arms. CFQ-R respiratory scores will be expressed as
mean ± standard deviation and statistical significance
assessed between the two arms at visit 4 using a 2-sample
t-test. A Kaplan-Meier plot will be used to graphically
display estimates of the survivor function for the propor-
tion of patients who do not have an exacerbation through
day 118. Hazard ratios and 95% confidence intervals due
to treatment will be calculated using a Cox proportional
hazards regression model. Pre-specified potential vari-
ables that may be adjusted for include gender, season of
enrollment, and center.
Our third hypothesis is that the treatment will have
similar effects with regards to the development of anti-
microbial resistance and adverse events compared to
placebo. There has been concern in previous methicillin-
sensitive Staphylococcus aureus treatment studies of an
increased risk of gram-negative pathogen acquisition;
therefore, we will monitor for this development [13].
Rates of occurrence of development of microbial resist-
ance, gram-negative pathogens will be summarized sep-
arately by treatment arm. Between-group comparisons
will be made using a χ2 test or Fishers exact test.
Adverse event rates will be coded by body system and
MedDra classification term. Adverse events will be tabu-
lated by treatment group and will include the number of
patients for whom the event occurred, the rate of occur-
rence, and the severity and relationship to study drug.
Fisher’s exact test will be used to compare the various
treatment groups with respect to incidence of the more
commonly occurring adverse events.
No interim analyses are planned. A safety analysis will
be planned after the first 16 adults are enrolled. If the
DSMB agrees based on initial safety data, enrollment
eligibility will then be expanded to include those aged 12–
17 as well.
Sample size
This study is powered on the primary outcome: the per-
centage of patients that are induced sputum negative for
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20 experimental and 20 control patients. There are no
treatment studies published in CF patients with persist-
ent MRSA to guide the assumptions for the primary out-
come for the two arms. In fact, the results from this
study will be used to power future multi-center trials.
Based on our experience, treatment with oral antibiotics
in those with persistent MRSA results in an approximate
eradication rate of 15–25%. An experimental arm eradi-
cation rate of 75% would be considered significant,
though some may even consider a lower percentage sig-
nificant as well. Based on these assumptions, we have
greater than 80% power if the MRSA eradication rate in
the experimental arm is at least 65%, assuming a 20%
eradication rate in the placebo arm.
Discussion
MRSA pulmonary infection is a clinically significant com-
plication for individuals with cystic fibrosis. The dramatic
increase in the prevalence of MRSA infection in CF and
the new understanding that persistent infection with this
resistant pathogen increases the rate of decline of lung
function and shortens survival for CF patients has made
finding an effective and safe treatment approach an urgent
need. Unfortunately, there is currently no clear data as
how to best treat persistent MRSA infection in CF. This
trial will evaluate the efficacy and safety of a particularly
promising treatment protocol utilizing inhaled vancomycin
and multiple oral antibiotics to eradicate MRSA from CF
patients with known persistent MRSA infection. Results of
this trial will provide guidance both for CF clinicians and
for future investigative efforts directed at this increasingly
important challenge in CF.
Trial status
The first patient was enrolled in October 2012. Recruit-
ment is ongoing.
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